Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02922881
Other study ID # 16-013075
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 8, 2017
Est. completion date September 30, 2021

Study information

Verified date December 2021
Source Children's Hospital of Philadelphia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ulcerative colitis is a chronic inflammatory disease primarily involving the colon and has long been considered to be due to a dysregulated immune response targeting the colon, and involves unknown environmental factors. Currently, no effective therapy targets the microbiota or its interaction with the colonic epithelium. Diet has a significant impact on the composition of the microbiota; however, no dietary intervention to date has proven effective for induction of remission. The primary objective of this study is to determine whether the Ulcerative Colitis Diet (UCD) can induce remission or response in pediatric UC patients with active mild to moderate UC on a stable medication.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date September 30, 2021
Est. primary completion date September 30, 2021
Accepts healthy volunteers No
Gender All
Age group 8 Years to 19 Years
Eligibility Inclusion Criteria: - Informed consent - Established diagnosis of UC - Age: 8-19 (inclusive) - Mild to moderate active disease, 10<PUCAI<45 - Stable medication (IMM/5ASA) use or no medication use for the past 6 weeks. - Participant has agreed to follow the UCD for 12 weeks Exclusion Criteria: - Any proven current infection such as positive stool culture, parasite or C. difficile within the past 4 weeks - Antibiotic or corticosteroid use in the past 2 weeks - Use of biologics in present or in the past - PUCAI>45 - Acute severe UC in the previous 12 months - Current extra intestinal manifestation of UC - Primary Sclerosing Cholangitis (PSC) or liver disease - Pregnancy - Known food allergy to mandatory foods in the UCD

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Ulcerative Colitis Diet (UCD)
The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission

Locations

Country Name City State
United States The Children's Hospital of Philadelphia Philadelphia Pennsylvania

Sponsors (4)

Lead Sponsor Collaborator
Children's Hospital of Philadelphia IWK Health Centre, National Institutes of Health (NIH), Wolfson Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Remission Remission defined by the Pediatric Ulcerative Colitis Activity Index (PUCAI) At 6 weeks following enrollment
Secondary Dietary Compliance Using modified Medication Adherence Rating Scale (MARS) questionnaire Up to 12 weeks following enrollment
Secondary Change in C-reactive protein (CRP) between baseline and week 12 12 weeks
Secondary Change in erythrocyte sedimentation rate (ESR) between baseline and week 12 12 weeks
Secondary Change in fecal calprotectin (FCP) between baseline and week 12 12 weeks
Secondary Microbial composition of the gastrointestinal tract Change in the microbial composition of the stool and rectum from baseline to 12 weeks. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2